Bioventus (NASDAQ:BVS) Sets New 52-Week High – Still a Buy?

Bioventus Inc. (NASDAQ:BVS) reached a new 52-week high on Thursday . The company traded as high as $12.41 and last traded at $12.4190, with a volume of 35775 shares. The stock had previously closed at $11.97.

Analyst Ratings Changes

A number of research analysts have recently commented on BVS shares. CJS Securities began coverage on Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Tuesday, June 16th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Bioventus currently has an average rating of “Buy” and an average target price of $14.75.

Bioventus Stock Down 3.0%

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The stock’s fifty day simple moving average is $9.88 and its two-hundred day simple moving average is $9.14. The stock has a market capitalization of $1.01 billion, a P/E ratio of 29.41, a price-to-earnings-growth ratio of 1.58 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, research analysts expect that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hillsdale Investment Management Inc. lifted its position in shares of Bioventus by 148.7% in the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock worth $6,128,000 after purchasing an additional 401,230 shares during the period. Wesbanco Bank Inc. bought a new position in Bioventus during the first quarter worth $895,000. Legato Capital Management LLC lifted its holdings in Bioventus by 1,042.8% in the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock valued at $1,023,000 after buying an additional 125,525 shares during the period. Inspire Investing LLC bought a new stake in Bioventus during the first quarter valued at $1,670,000. Finally, Anderson Financial Strategies LLC grew its holdings in Bioventus by 58.3% during the 4th quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock worth $1,586,000 after acquiring an additional 78,488 shares during the period. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.